Chad is a member of the Intellectual Property Practice Group. He focuses his practice on Hatch-Waxman and biosimilar patent litigation. With a background in biochemistry, Chad brings both legal and scientific knowledge when counseling generic pharmaceutical clients. Chad’s past academic and laboratory experience synthesizing highly conjugated organic compounds allows him to approach pharmaceutical cases from a development scientist’s perspective.
Articles in the National Law Review database by Chad F. Watson